Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery

NCT ID: NCT01521481

Last Updated: 2014-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the analgesic efficacy of an ultrasound-guided inguinal field block (block of the genitofemoral, iliohypogastric and ilioinguinal nerve).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Inguinal hernia repair accounts for 10-15% of all operations in general surgery. Moderate to severe pain can occur at the first day after inguinal hernia repair in 25% of patients at rest and in 60% during activity. On day 6 after the operation the incidence can be as high as 11% at rest and 33% during activity.

Ultrasound imaging for regional anesthesia techniques have improved the success and safety rate of nerve blocks. We hypothesized that a procedure consisting of an ultrasound-guided inguinal field block (genitofemoral, iliohypogastric and ilioinguinal nerve block and incision line infiltration) could effectively control postoperative pain compared to selective unilateral subarachnoid anesthesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inguinal Hernia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Triple inguinal nerve block

Ropivacaine 5 mg/ml

Group Type EXPERIMENTAL

Triple inguinal nerve block.

Intervention Type OTHER

Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.

Unilateral subarachnoid anesthesia

Bupivacaine 10 mg/ml

Group Type ACTIVE_COMPARATOR

Unilateral subarachnoid anesthesia

Intervention Type OTHER

Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triple inguinal nerve block.

Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.

Intervention Type OTHER

Unilateral subarachnoid anesthesia

Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Regional anesthesia for the groin. Regional anesthesia for the groin.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI (Body mass index) \< 30
* Non severe liver, renal or cardiac disease
* No allergy or contraindications to any of the study drugs
* American Hernia Society Score type I-II-IV-V hernia
* No pain or chronic analgesic administration in the preoperative period
* No previous surgery of the inguinal region
* Normal coagulation parameters and platelet count (\> 100.000).
* Dicumarol and aspirin suspension for \> 7 days
* Correctly administrated premedication
* No systemic infections
* No contraindications to subarachnoid anesthesia

Exclusion Criteria

* BMI (Body mass index) \> 30
* Severe liver, renal or cardiac disease
* Allergy or contraindications to any of the study drugs
* American Hernia Society Score type III-VI-VII-0 hernia
* Pain or chronic analgesic administration in the preoperative period
* Previous surgery of the inguinal region
* Anormal coagulation parameters and platelet count (\< 100.000).
* No dicumarol and aspirin suspension for \> 7 days
* Incorrectly administrated premedication
* Systemic infections
* Contraindications to subarachnoid anesthesia
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Azienda Ospedaliera San Gerardo di Monza

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhirajr Mokini M.D.

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhirajr Mokini, M.D.

Role: PRINCIPAL_INVESTIGATOR

San Gerardo Hospital

Pablo Mauricio Ingelmo, M.D.

Role: STUDY_DIRECTOR

San Gerardo Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

San Gerardo Hospital

Monza, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AR HSG 03 2010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.